ONCOLOGY REPORTS 15: 565-569, 2006
565
Germline mutations of BRCA1 in two Korean
hereditary breast / ovarian cancer families
TAE-JOONG KIM, KYUNG-MEE LEE, CHEL HUN CHOI, JEONG-WON LEE,
JE-HO LEE, DUK-SOO BAE and BYOUNG-GIE KIM
Department of Obstetrics and Gynecology, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, Korea
Received September 19, 2005; Accepted November 11, 2005
Abstract. Testing for cancer susceptibility gene, in particular
mutations in the BRCA1 gene in association with hereditary
breast/ovarian cancer has been extensively studied. We
investigated germline mutations in the BRCA1 gene from two
Korean hereditary breast/ovarian cancer families using direct
DNA sequencing. Blood samples of the thirteen family
members were studied. We found three missense mutations;
3232 A→G, 2731 C→T, 3667 A→G. These mutations were
involved in the altered coding of amino acids. According to
the BIC database, clinical significance of these mutations is
regarded as favor polymorphisms. Therefore, these genetic
variations are not believed to be involved in the development of
the disease, but may be associated with breast/ovarian cancers
in another yet undefined way. For further clinical significance
of these variations, additional study such as a case-controlled
haplotyping study is needed.
Introduction
Breast cancer is the most common cancer in Korean women
and the incidence of ovarian cancer is the ninth in order with
increasing tendency (1). Although most cases of breast and
ovarian cancer occur sporadically in women with no previous
personal or family history of cancer, it is well known that 5-7%
of breast cancers and 10% of ovarian cancers are hereditary
with a pattern of autosomal-dominant inheritance (2).
Testing for cancer susceptibility genes support a variety
of clinical decisions by providing results that indicate risk
for future disease, confirmation of diagnoses and more
recently, therapeutic selection and prognosis. The BRCA1
associated with hereditary breast/ovarian cancer is the most
extensively studied cancer susceptible gene to date. BRCA1
_________________________________________
Correspondence to: Dr Byoung-Gie Kim, Department of Obstetrics
and Gynecology, Samsung Medical Center, Sungkyunkwan University
School of Medicine, 50 Ilwon-Dong, Kangnam-Ku, Seoul 135-710,
Korea
E-mail: bgkim@smc.samsung.co.kr
Key words: ovarian neoplasms, breast neoplasms, genes, BRCA1,
Koreans
was originally isolated using positional cloning techniques
(3). Germline alterations in the gene result in a predisposition
for developing early-onset breast and ovarian cancer with a
penetrance as high as 85% and 65%, respectively (4). The
protein products of the BRCA1 gene regulate, at least in part,
transcriptional activation, DNA repair, cell-cycle checkpoint
control and chromosomal re-modeling (5).
Although about 1500 genetic variants of BRCA1 have
been described in the Breast Cancer Information Core (BIC)
(http://research.nhgri.nih.gov/bic/), there is little data on the
contribution of germline BRCA1 mutations to breast and/or
ovarian cancer in Korea (6,7). To detect mutations, a variety
of mutation screening methods, including dHPLC, CSGE,
DGGE, SSCP and direct DNA sequencing have been adopted
in Korea (8). Direct DNA sequencing is regarded as the ‘gold
standard’ for sensitivity (9).
To further understand the implication of genetic variants,
we performed mutational analysis on the BRCA1 gene in two
families having two or more affected first- or second-degree
relatives with breast and/or ovarian cancer using direct DNA
sequencing.
Materials and methods
Subjects. We evaluated germline mutations of BRCA1 from
13 blood samples in two families including two or more
affected first- or second-degree relatives with breast and/or
ovarian cancer. One proband is a patient with ovarian cancer
and the other one is a patient with breast cancer (Fig. 1).
Genomic DNA isolation. Using an iNtRon blood genomic
DNA purification kit (iNtRON Biotechnology, Seoul, Korea)
and in accordance with the manufacturer's protocols, genomic
DNA was extracted from peripheral blood lymphocytes.
PCR program. DNA was amplified by PCR for the 24 exons
of the BRCA1 gene using previously published primer sets
(10) that yielded 169- to 400-base pair products. Because of
its size, exon 11 was screened using 19 overlapping primer
sets (Table I). PCRs were performed with genomic DNA
containing 50 ng of genomic DNA, 1 µl of each primer at
5 pmol/µl, 2 µl of a mixture of dNTPs (each at 2.5 mM), 2.5 µl
of 10X PCR buffer, 1 µl of Taq polymerase, and distilled
water was added to a final volume of 25 µl. For amplification,
566
KIM et al: BRCA1 IN KOREAN CANCER FAMILIES
Table I. BRCA1 primers used for amplification and SSCP analysis of exon 11.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Exon
Sense
Antisense
Product length (bp)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
11.0
5'-GTGAATTTTCTGAGACGGATGTA
5'-GAGCTGGCATGAGTATTTGTG
169
11.1
5'-AGAGGCATCCAGAAAAGTATCAGG
5'-GGGAGTCCGCCTATCATTACA
239
11.2
5'-ACAGCCTGGCTTAGCAAGGAG
5'-CCCCATCATGTGAGTCATCAGA
278
11.3
5'-AGAAACTGCCATGCTCAGAGAATC
5'-ATGAGGATCACTGGCCAGTAAGTC
245
11.4
5'-TGTATTGGACGTTCTAAATGAGGT
5'-TTGTGAGGGGACGCTCTTGTA
266
11.5
5'-GCATTTGTTACTGAGCCACAGATA
5'-TCTATTGGGTTAGGATTTTTCTCA
263
11.6
5'-CAAACGGAGCAGAATGGTCA
5'-GCCTGGTAGAAGACTTCCTCCTC
244
11.7
5'-TCCACAATTCAAAAGCACCTAAAA
5'-CTCTGGGAAAGTATCGCTGTCAT
299
11.8
5'-GCAACTGGAGCCAAGAAGAGTAAC
5'-TTTGCAAAACCCTTTCTCCACTTA
256
11.9
5'-TTGTCAATCCTAGCCTTCCAAGAG
5'-TTTTGCCTTCCCTAGAGTGCTAAC
224
11.10
5'-TATGGCACTCAGGAAAGTATCTCG
5'-GCGCTTTGAAACCTTGAATGTAT
270
11.11
5'-ACAGTCGGGAAACAAGCATAGAA
5'-TTTGGCATTATCAACTGGCTTATC
314
11.12
5'-AGGCTTTCCTGTGGTTGGT
5'-TTACGGCTAATTGTGCTCACTG
306
11.13
5'-AACATTCCAAGTACAGTGAGCACA
5'-AGATGCATGACTACTTCCCATAGG
378
11.14
5'-TCCTGGAAGTAATTGTAAGCATCC
5'-GGCCCCTCTTCGGTAACC
325
11.15
5'-TCCTAGCCCTTTCACCCATACA
5'-AGATGCCTTTGCCAATATTACCTG
274
11.16
5'-TGCTACCGAGTGTCTGTCTAAGAA
5'-AGAAAGGATCCTGGGTGTTTGTAT
209
11.17
5'-GCTAGCTTGTTTTCTTCACAGTGC
5'-AAGTTTGAATCCATGCTTTGCTCT
218
11.18
5'-CAGGGAGTTGGTCTGAGTGAC
5'-GCTCCCCAAAAGCATAAAC
181
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
each sample was denatured at 94˚C for 2 min and subjected
to 35 cycles of PCR (94˚C for 30 sec, 55˚C for 15 sec, 60˚C
for 15 sec, and extension at 72˚C for 1 min on Applied
Biosystems DNA thermal cycler); this was followed by
incubation at 72˚C for 10 min.
SSCP analysis. For SSCP analysis, the PCR products were
mixed with an equal volume of formamide loading dye. The
mixture was heated at 95˚C for 5 min to denature the DNA.
After denaturation, the sample was chilled on ice for a few
minutes. The samples were then run on an acrylamide gel under
non-denaturing conditions in an electrophoresis apparatus.
Electrophoresis was carried out in 0.5X TBE for 3-5 h at 4˚C.
Direct sequencing. All sequence variants were confirmed by
using the PCR products of each sequence variant and Big
Dye on an ABI3100 DNA sequencer (Applied Biosystems).
Results
In two breast and/or ovarian cancer families, 13 blood samples
were evaluated for germline mutations in BRCA1. SSCP
analysis using PCR products of the whole BRCA1 gene
revealed that there were band shifts in only exon 11 compared
to the wild-type BRCA1 gene (Fig. 2). All members of Park
family showed a band shift in the location of the exon 11.13,
except for a son of the proband who did not have the genetic
mutation (Fig. 1). Also, all members of the Moon family had
two genetic mutations in SSCP. The locations identified were
exon 11.11 and exon 11.14.
Direct DNA sequencing of exon 11, which is known as a
‘hot spot’, found three missense mutations as follows: 3232
A →G, 2731 C →T, 3667 A →G (Fig. 3). These mutations
altered coding of amino acids in the study family.
To understand the clinical significance of these missense
mutations, we referred to the BIC database, which has about
1500 genetic variations registered. All of the genetic mutations
that we found in two Korean families have already been entered
into the BIC database. They are identified as favor polymorphisms. In addition, they have reference SNP numbers
(Table II).
Discussion
The BRCA1 gene is located on chromosome 17q21 and has a
total length of about 100 kb. This gene consists of 24 exons
and the coding region starts at the middle of exon 2. The size
of the mRNA is 7.8 kb and BRCA1 product, localized in the
nucleus (11), is a phosphorylated protein that consists of
1863 amino acids and has a molecular weight of 220 kDa.
The phosphorylation is dependent on the cell cycle (12).
BRCA1 is known to have several functions. One is repair of
DNA damage by interacting with Rad51 and participation in
homologous recombination (13). Another is regulation of gene
expression by performing as a cofactor of many transcription
factors. For instance, BRCA1 functions as a coactivator in p53-
ONCOLOGY REPORTS 15: 565-569, 2006
567
Figure 1. Korean breast and breast-ovarian cancer families with germline BRCA1 missense mutations. Cancer types, age at diagnosis and mutation status are shown.
Confirmed from blood sample to carry mutation; ^Confirmed from blood sample not to carry mutation; Circles, patients with cancer; Br, breast cancer; Ov,
ovarian cancer; Cx, cervical cancer.
*
Figure 2. Single-strand conformational polymorphism (SSCP) assay for germline mutation in BRCA1 exon 11. Lanes 1, 2, exon 11.13 PCR products; Lanes 3, 4,
exon 11.11 PCR products; Lanes 5, 6, exon 11.14 PCR products; Wt, wild-type; Mt, mutant type.
dependent transcription (14) and as a corepressor in estrogen
response transcription (15). Therefore, BRCA1 is believed to
regulate cell growth, apoptosis and cell function by regulating
gene expression. The other function is to maintain chromosomal
stability. BRCA1-deficient cultured cells show decreased cell
growth and hypersensitivity to ionizing radiation, resulting in
DNA damage associated with chromosomal abnormalities
(16-18). Overall, BRCA1 in its non-mutated form function as
a tumor suppressor gene. The process of cancer development
in individuals with germline mutations in the BRCA1 gene
requires somatic inactivation of the remaining wild-type allele.
The BRCA1 gene is very large and hundreds of specific
different mutations of BRCA1 have been described. Most of
the mutations are unique to the family in which they occur
(19). Myriad Genetic Laboratories, Inc., where most variants
in BRCA1 were discovered and classified, classify genetic
variants as deleterious, suspected deleterious, uncertain
clinical significance, favor polymorphism and polymorphism/
neutral (20). Mutations that result in a truncated protein can
be assumed to be deleterious. The most common deleterious
mutations for BRCA1 are non-sense or frame-shift mutations
that begin prior to, or at, codon 1853. In addition, some specific
missense mutations and splice mutations are recognized as
deleterious. Although many variations that are not deleterious
mutations have been found, many remain to be identified.
Ethnicity may affect genetic mutations. Founder mutations
have been identified in various ethnic groups including
Ashkenazi Jews, Icelanders, Russians, and Israelis (21-23).
However, it is still necessary to screen the entire sequences of
BRCA1 genes in Asian women. Most studies of BRCA1
mutations in Japan reported many frameshift or non-sense
mutations as well as polymorphisms and unclassified variants
in BRCA1 gene, but there appears not to be specific Japanese
‘hot spots’ for BRCA1 mutations (24). A previous study in 21
Korean hereditary breast/ovarian cancer families identified
only 5 deleterious mutations in BRCA1 gene; 2 frameshift and
3 non-sense mutations, without polymorphisms or unclassified
variants. They used the protein truncation test for exon 11 of
BRCA1 as a screening method (7). The present study found
three genetic variations in BRCA1 in two Korean families
with hereditary breast and/or ovarian cancer (Table II). All
mutations identified were also reported in the Japanese
568
KIM et al: BRCA1 IN KOREAN CANCER FAMILIES
Figure 3. Missense mutations identified by direct sequencing. Direct PCR based sequencing was performed on all samples in which a shift band pattern was
observed in SSCP analysis. (a) Park family: Left, wild-type sequence of a portion of exon 11; Right, missense mutation sequence of a portion of exon 11
(3232 A→G). (b) and (c) Moon family: Left, wild-type sequence of a portion of exon 11; Right, missense mutation sequences of a portion of exon 11 (2731
C→T), (3667 A→G).
Table II. Polymorphisms in BRCA1 gene.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Family
Exon
Codon
Nucleotide changea Amino acid change
Reference SNP (rs) number
BICb
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Park
11
1038
3232 A>G
Glu to Gly
16941
11
871
2731 C>T
Pro to Leu
799917
Moon
11
1183
3667 A>G
Lys to Arg
16942
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aNucleotide
number are based on U14680; bChange entered in the BIC database are marked as -.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
studies (24). According to the BIC database, three variations
are all regarded as favor polymorphisms. They are given
reference SNP (rs) numbers (http://www.ncbi.nlm.nih.gov).
Therefore, these genetic variations are not believed to be
causative mutations for cancer, but may be associated with
the disease in another yet undefined manner. For a more
detailed understanding of the clinical significance, further study
such as a case-controlled haplotyping is needed. Here we may
not have found any deleterious mutations reported in the
Korean cancer families, because of the small number of
samples studied. Instead, we identified polymorphisms, not
found in a previous study for Korean women, this difference
could have resulted from different screening methods.
At first, we used a single-strand conformational polymorphism (SSCP), which showed a band-shift in exon 11.
Then direct DNA sequencing was performed. Many studies
have used SSCP or denaturing high-performance liquid
chromatography (DHPLC), but direct DNA sequencing is
considered optimal and as the ‘gold standard’.
BRCA1-related breast cancers can be associated with a poor
prognosis, but BRCA1-related ovarian cancers are associated
with a high frequency of serous adenocarcinoma and a good
outcome (24). Among patients with FIGO stage III ovarian
cancer, the 5-year survival rate of BRCA1-mutation positive
patients is reported as 78.6%, as compared with only 30.3%
in control patients, with other etiologies for their ovarian
cancer (25). The clinicopathologic features of one proband
with ovarian cancer were consistent with the familial ovarian
cancer with a BRCA1 mutation. The proband had primary
surgery with adjuvant chemotherapy 14 years ago. Pathologic
diagnosis was stage IIIc serous adenocarcinoma. Recurrence
developed six years after the primary treatment and she had
cytoreductive surgery and palliative chemotherapy, total of
50 cycles to date. She has been very sensitive to platinumbased chemotherapy. One possible mechanism supporting the
favorable outcome in BRCA carriers with ovarian cancer is
the increased sensitivity to platinum induced DNA damage in
BRCA heterozygotes (26).
Although this study investigated a small number of
samples of the Korean BRCA1 families, it identified genetic
variations of BRCA1 genes through direct DNA sequencing
methods screening the entire sequences. All identified
ONCOLOGY REPORTS 15: 565-569, 2006
variations were favor polymorphisms and are therefore not
believed to be causative mutations in the development of the
breast/ovarian cancer. Because only a limited number of
cases have been analyzed in Korea, for further understanding
of the genetic variations in the BRCA1 gene in the Korean
population, additional study is required.
References
1. Ministry of Health and Welfare RoK: Annual report of cancer
registry programme in the Republic of Korea (2000.1-2000.12),
2003.
2. Claus EB, Schildkraut JM, Thompson WD and Risch NJ: The
genetic attributable risk of breast and ovarian cancer. Cancer 77:
2318-2324, 1996.
3. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K,
Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al: A
strong candidate for the breast and ovarian cancer susceptibility
gene BRCA1. Science 266: 66-71, 1994.
4. Easton DF, Ford D and Bishop DT: Breast and ovarian cancer
incidence in BRCA1-mutation carriers. Breast Cancer Linkage
Consortium. Am J Hum Genet 56: 265-271, 1995.
5. Kerr P and Ashworth A: New complexities for BRCA1 and
BRCA2. Curr Biol 11: R668-676, 2001.
6. Ahn SH, Hwang UK, Kwak BS, Yoon HS, Ku BK, Kang HJ,
Kim JS, Ko BK, Ko CD, Yoon KS, Cho DY, Kim JS and Son BH:
Prevalence of BRCA1 and BRCA2 mutations in Korean breast
cancer patients. J Korean Med Sci 19: 269-274, 2004.
7. Kang HC, Kim IJ, Park JH, Kwon HJ, Won YJ, Heo SC, Lee SY,
Kim KH, Shin Y, Noh DY, Yang DH, Choe KJ, Lee BH, King SB
and Park JG: Germline mutations of BRCA1 and BRCA2 in
Korean breast and/or ovarian cancer families. Hum Mutat 20: 235,
2002.
8. Eng C, Brody LC, Wagner TM, Devilee P, Vijg J, Szabo C,
Tavtigian SV, Nathanson KL, Ostrander E and Frank TS:
Interpreting epidemiological research: blinded comparison of
methods used to estimate the prevalence of inherited mutations
in BRCA1. J Med Genet 38: 824-833, 2001.
9. Orban TI, Csokay B and Olah E: Sequence alterations can mask
each other's presence during screening with SSCP or heteroduplex
analysis: BRCA genes as examples. Biotechniques 29: 94-98,
2000.
10. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED,
Rowell SE and King MC: Confirmation of BRCA1 by analysis
of germline mutations linked to breast and ovarian cancer in ten
families. Nat Genet 8: 399-404, 1994.
11. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF,
Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH,
Kanter MH, Cohen S, Calzone FJ and Slamon DJ: Localization of
human BRCA1 and its loss in high-grade, non-inherited breast
carcinomas. Nat Genet 21: 236-240, 1999.
569
12. Ruffner H and Verma IM: BRCA1 is a cell cycle-regulated
nuclear phosphoprotein. Proc Natl Acad Sci USA 94: 7138-7143,
1997.
13. Moynahan ME, Chiu JW, Koller BH and Jasin M: Brca1 controls
homology-directed DNA repair. Mol Cell 4: 511-518, 1999.
14. Ouchi T, Monteiro AN, August A, Aaronson SA and Hanafusa H:
BRCA1 regulates p53-dependent gene expression. Proc Natl Acad
Sci USA 95: 2302-2306, 1998.
15. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG,
Yuan F, Auborn KJ, Goldberg ID and Rosen EM: BRCA1
inhibition of estrogen receptor signaling in transfected cells.
Science 284: 1354-1356, 1999.
16. Powell SN and Kachnic LA: Roles of BRCA1 and BRCA2 in
homologous recombination, DNA replication fidelity and the
cellular response to ionizing radiation. Oncogene 22: 5784-5791,
2003.
17. Venkitaraman AR: Functions of BRCA1 and BRCA2 in the
biological response to DNA damage. J Cell Sci 114: 3591-3598,
2001.
18. Welcsh PL and King MC: BRCA1 and BRCA2 and the genetics
of breast and ovarian cancer. Hum Mol Genet 10: 705-713, 2001.
19. Welcsh PL, Owens KN and King MC: Insights into the functions
of BRCA1 and BRCA2. Trends Genet 16: 69-74, 2000.
20. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE,
Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR
and Critchfield GC: Clinical characteristics of individuals with
germline mutations in BRCA1 and BRCA2: analysis of 10000
individuals. J Clin Oncol 20: 1480-1490, 2002.
21. Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A,
Agnarsson BA, Eiriksdottir G, Johannsson OT, Borg A,
Ingvarsson S, Easton DF, Egilsson V and Barkardottir RB: High
prevalence of the 999del5 mutation in icelandic breast and ovarian
cancer patients. Cancer Res 56: 3663-3665, 1996.
22. Robles-Diaz L, Goldfrank DJ, Kauff ND, Robson M and Offit K:
Hereditary ovarian cancer in Ashkenazi Jews. Fam Cancer 3:
259-264, 2004.
23. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M,
McAdams M, Timmerman MM, Brody LC and Tucker MA:
The risk of cancer associated with specific mutations of BRCA1
and BRCA2 among Ashkenazi Jews. N Engl J Med 336:
1401-1408, 1997.
24. Arai M, Utsunomiya J and Miki Y: Familial breast and ovarian
cancers. Int J Clin Oncol 9: 270-282, 2004.
25. Aida H, Takakuwa K, Nagata H, Tsuneki I, Takano M, Tsuji S,
Takahashi T, Sonoda T, Hatae M, Takahashi K, Hasegawa K,
Mizunuma H, Toyoda N, Kamata H, Torii Y, Saito N, Tanaka K,
Yakushiji M, Araki T and Tanaka K: Clinical features of ovarian
cancer in Japanese women with germ-line mutations of BRCA1.
Clin Cancer Res 4: 235-240, 1998.
26. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA and
Karlan BY: Improved survival in women with BRCA-associated
ovarian carcinoma. Cancer 97: 2187-2195, 2003.